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INTRODUCTION
In patients with intermediate or poor risk acute myeloid leukemia (AML) or advanced
myelodysplastic syndrome (MDS), allogeneic hematopoietic stem cell transplantation (ASCT)
remains the only curative treatment (1). Although overall survival (OS) of these patients has
improved over the past few decades, relapse rates remain high (2, 3). Following ASCT, up to 50% of
patients will relapse, with the majority occurring the first 48 months (4, 5). The prognosis of patients
who relapse is poor, with less than 20% surviving 2 years (6). Risk factors for relapse include reduced
intensity conditioning-regimen, absence of graft-versus-host disease (GVHD), loss of donor
chimerism, and the presence of measurable residual disease (MRD) (5, 7). Currently utilized
methods for MRD detection include multi-parametric flow cytometry, quantitative polymerase
chain reaction, and next-generation sequencing (8, 9). MRD detection is an important prognostic
tool as MRD positivity portends a higher risk of relapse (10). Patients treated for AML who achieve
morphologic complete remission (CR) but have MRD positivity at the time of ASCT have higher
relapse rates and worse OS than MRD-negative patients (11). Similarly, patients with AML who
develop MRD positivity after ASCT have a higher incidence of relapse and worse OS compared to
those who remain MRD-negative (12). Given the poor prognosis of AML patients who become
MRD-positive, strategies to prevent relapse are needed. Herein, we present arguments for and
against the use of hypomethylating agents (HMA) to prevent morphologic AML/MDS relapse in
this patient population. This review will focus on the recently published RELAZA-2 trial, one of the
largest studies to investigate pre-emptive MRD-guided treatment using HMA (13).
RELAZA-2 was a German-multicentered, open-label, single-arm, phase II study assessing the
efficacy of azacitidine in adults with MDS or AML who achieved morphologic CR after conventional
chemotherapy or ASCT but developed MRD positivity within 24 months of treatment. MRD was
detected by ≤80% CD34+ donor chimerism in ASCT patients, or an increase in NPM1 mutation or
fusion genes including DEK-NUP214, RUNX1-RUNX1T1, or CBFb-MYH11, above 1% in the
blood or bone marrow without concurrent hematologic relapse. Patients screened using CD34+
donor chimerism were monitored monthly for the first 6 months, followed by every 3 months until
month 24. Patients screened using NPM1 or fusion genes had either bone marrow assessment every
3 months or peripheral blood assessment monthly. In patients who became MRD-positive,
azacitidine 75mg/m2 days 1-7 was given every 29 days for 24 cycles. MRD was monitored after 6
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cycles, with MRD-negative patients eligible for treatment de-
escalation. The primary endpoint was relapse-free survival at 6
months after starting azacitidine.
Of the 198 patients screened, 53 (AML, n = 48; MDS, n = 5;
prior treatment: chemotherapy, n = 29; ASCT, n = 24) became
MRD-positive and were eligible for treatment. Median follow
up was 13 months after the start of MRD-guided therapy.
After 6 months of azacitidine, 31 patients (58%, 95% CI 44-72)
were relapse free and alive (p < 0.0001; one-sided binomial test
for null hypothesis pexp < 0.3). 19 of the 31 patients achieved
MRD-negativity; the other 12 patients were MRD-positive but
were without hematologic relapse. At 12 months, relapse-free
survival (RFS) was 46%, and the OS was 75%. Thirteen
patients died: 10 from relapse and 3 from infection (1
possibly related to azacitidine). The most common high-
grade adverse event was neutropenia which occurred in 42
patients (79%). Of the 198 patients who remained MRD-
negative (n = 138), 12-month RFS was 88% and 12-month
OS was 91%.
Among the ASCT patients (n = 24), 10 were on systemic
immunosuppression at the time of treatment initiation.
Four patients without a history of GVHD developed GVHD
during azacitidine treatment. Two received concomitant donor-
lymphocyte infusion (DLI) and 4 were on systemic
immunosuppression 6 months after starting MRD-guided
treatment. Out of the 24 ASCT patients, 17 (71%) were relapse-
free at 6 months with 13 of the 17 achieving MRD-negativity.
POINT: THE CASE FOR AZACITIDINE IN
MRD-POSITIVE DISEASE
There is sufficient evidence that MRD positivity yields a worse
prognosis for patients with intermediate and poor-risk AML or
MDS after chemotherapy or ASCT (10–12). Prior to the
RELAZA-2 trial, the single-center, phase II Relaza-1 trial
investigated pre-emptive treatment of 20 patients with poor-
risk AML or MDS who were MRD-positive after ASCT (14).
MRD positivity in this group was defined as CD34+ donor
chimerism less than 80%. These patients were treated with at
least 4 cycles of azacitidine. Ultimately, 16 patients responded,
with a majority achieving the goal of CD34+ donor chimerism
greater than 80%. Thirteen of the 20 patients eventually
developed hematological relapse, however, the median time to
relapse (TTR) was 231 days which was significantly delayed
compared to historical controls.
Relaza-2 sought to confirm these results and demonstrated
clear improvement in RFS after detection of MRD positivity (13).
Median TTR was 422 days vs. historic trials demonstrating
median TTR at 126, 255, and 61 days, respectively (12, 15, 16).
Over one-third of the patients displayed a major MRD response.
This group of patients had significantly better outcomes than
patients with lesser responses. In fact, at 23 months, more than
60% of them were alive and relapse free. Azacitidine was well
tolerated, with few significant adverse effects. As expected,
neutropenia rates were high; however, rates of neutropenic
fever remained low. Additionally, this study reinforced the
importance of achieving MRD negativity in preventing disease
relapse in this patient population.
Other studies have investigated HMA maintenance therapy
following ASCT in patients with AML and MDS. An early phase
trial demonstrated that low-dose decitabine maintenance was
well tolerated in patients 50–100 days following ASCT, without a
major impact on GVHD incidence (17). Preliminary results
comparing low-dose azacitidine maintenance vs. observation
after ASCT showed decrease in relapse rates (25.8 vs. 66.7%),
increase in TTR (not reached vs. 4.1 months; p < 0.001), and
improvement in OS (27.5 months vs. 7.6 months; p < 0.0001)
favoring the azacitadine group (18). Azacitidine did not appear
to increase the risk of GVHD in this study. These results suggest
that HMAs are both safe and effective in the post-ASCT setting.
Patients with intermediate or poor-risk AML orMDS who are
MRD-positive after chemotherapy or ASCT have unacceptably
high rates of relapse and death. Further therapies to achieve
MRD negativity in this setting are indicated. Maintenance
azacitadine has shown benefit in improving RFS, delaying
hematologic relapse with a tolerable side effect profile and
should be a consideration in this patient population.
COUNTERPOINT: THE CASE AGAINST
AZACITIDINE IN MRD-POSITIVE DISEASE
Although RELAZA-2 demonstrated improved RFS at 6 months,
this was a non-randomized phase II study without a control group
and had a small, heterogeneous patient population including those
previously treated with either chemotherapy alone or ASCT. Since
this study combined both treatment groups, it is difficult to
generalize the outcomes as MRD-positive patients post-ASCT
are not the same population as the MRD-positive patients post-
chemotherapy. Additionally, post-hoc analysis comparing
outcomes between MRD-responders and non-responders
showed there was no difference in OS at 6 months (HR, 0.4;
95% CI: 0.1–1.3, p = 0.112). The methodology used for MRD
monitoring in this study, specifically using CD34+ donor
chimerism of less than 80% in post-ASCT patients, has not been
verified as a standard approach. There were also two post-ASCT
patients who received a concomitant DLI which may have
augmented treatment outcomes.
The complications of maintenance with azacitidine should
also be taken into consideration, specifically the increase in
hematologic toxicity and severe infection risk observed in
Relaza-2 and a recent study investigating post-ASCT
maintenance decitabine (17). In addition, although there is
evidence that HMAs may immunologically mitigate GVHD
while preserving the graft-versus-leukemia effect (19), there
were four patients in the RELAZA-2 study who developed
GVHD after azacitidine who had no prior history GVHD.
Further studies are needed to assess the immunomodulatory
impact of HMA in the post ASCT period.
In the era of cost-conscious health care, the financial burden
of monthly azacitidine infusions should also be weighed against
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the overall benefit of treatment. Similarly, treatment impact on
patient quality of life should be considered given frequent office
visits and need for repeated bone marrow assessment to monitor
MRD response.
It is also unclear if standard azacitidine is the optimal
maintenance treatment of choice in this setting. CC-486, a novel
oral formulation of azacitidine, showed good tolerability and low
rate of relapse in an early phase I/II study in AML patients who
achieved CR following ASCT (20). More recently, the phase III
randomized, double blinded QUAZAR AML-001 trial investigated
CC-486 maintenance in AML patients in first CR who are not
candidate for curative consolidation such as ASCT. Results
comparing the CC-486 to placebo groups showed significant
improvements in OS (24.7 vs. 14.8 months; HR = 0.69, 95% CI:
0.55–0.86, p = 0.0009) and RFS (10.2 vs. 4.8 months; HR = 0.65,
95% CI: 0.52–0.81, p = 0.0001) (21). MRD status is being
monitored in this study but those results have not yet been
reported. Based on this study, CC-486 was recently approved by
the Food and Drug Administration as maintenance treatment for
AML patients in first CR who are unable to proceed to intensive
consolidation therapy. Ongoing studies investigating AML
maintenance treatment with azacitidine in combination with
venetoclax and pembrolizumab, respectively, are being conducted
and will evaluate the impact on MRD status [NCT03769532 and
NCT04062266]. These studies may provide further insight on the
optimal strategy in MRD-guided treatment of AML.
DISCUSSION
Given the dismal outcomes in relapsed AML and MDS,
treatment of patients with MRD-positive disease may be an
effective option to prevent relapse. The optimal management of
these patients is still being evaluated but promising results were
seen in the Relaza-2 trial which showed improvement in RFS and
TTR using azacitidine in MRD-positive patients. The Relaza-2
authors hypothesized that the proposed mechanism of HMA in
the ASCT group is immunologic induction of regulatory T-cells
that mitigate GVHD while preserving the graft-versus leukemia
effect, which has also been supported by pre-clinical data (22,
23). Questions that remain unanswered include the effect of
HMA on ASCT complications, including GVHD, and whether
the treatment toxicities, both physical and financial, are worth
the overall benefit. Given the lack of alternative therapies and
poor outcomes in this patient population, we would recommend
consideration of maintenance azacitidine which appears effective
in preventing frank relapse of AML andMDS. Future studies that
could provide more insight on MRD-guided therapy include
evaluating maintenance treatment in more homogenous patient
populations such as separating ASCT patients from those who
received chemotherapy alone. Investigating different HMA
dosing levels and schedules, as well as alternate HMA
formulations such as CC-486, may improve treatment efficacy,
decrease toxicity, and ultimately decrease treatment burden.
Methods for testing MRD could also be evaluated to determine
the optimal strategy for MRD monitoring. Combining HMA
with novel agents could yield a more effective maintenance.
Ongoing randomized trials will hopefully provide further
insight and help identify the optimal treatment strategy
moving forward.
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